Vilon
Research OnlyA synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework. Claimed to support thymus gland function and immune modulation. No Western clinical validation exists; all research originates from Russian institutes.
KE · Lys-Glu · Dilysine · KE dipeptide
Mostly preclinical · 2 human studies
- Preclinical
- 67%
- Clinical
- 13%
Based on 15 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 17: best human-relevant evidence is ex-vivo only — Vilon stimulated human thymocyte/NOR ribosomal activity and blast transformation (15455093) and reactivated chromatin in cultured lymphocytes from old donors (15105581); no in-vivo human study exists, so 1A caps at animal-data tier (6), high RoB (1B 2), human N<50 (1C 1), indirect surrogate endpoints (1D 3), with a modest multi-model preclinical program (1E 5). Mechanism 36: target only inferred (proposed direct DNA/chromatin binding, no Ki/IC50 or knockout; 2A 10), proximal signaling partly mapped (sphingomyelin pathway 12420072, gene-expression shifts incl. NF-kB 32399807; 2B 12), limited dose-response (2C 6), confirmed in in-vivo mammals (2D 8). Plausibility 57: mechanism -> surrogate established but surrogate -> immune benefit inferred (3A 16), coherent with immunosenescence biology (3B 20), same-class short-peptide analogy (3C 14), but moderately broad immune+longevity+oncostatic claim (3D 7). Global Coverage 26: nearly all work from the Khavinson/St. Petersburg cluster with one partial Georgian collaboration (4A 8), narrow geographic/institutional breadth (4B 8), ~15 studies (4C 10), no governance review anywhere (4D 0). Community Experience 21: negligible documented real-world use (5A 4), limited track record (5B 7), no reports to assess consistency (5C 4), no recurring adverse signal but minimal exposure (5D 6). Effectiveness not established: no quantified human efficacy estimate and no meaningful community effect signal.
The proposed mechanisms of Vilon are based entirely on Russian research. No independent Western validation or controlled human clinical trials exist.
How It Works (Simplified)
Vilon targets immune function through thymus gland modulation:
Proposed to stimulate thymus gland function, promoting thymocyte proliferation and T-cell maturation that typically decline with age.
Short peptides like KE are claimed to penetrate cell nuclei and interact with DNA/chromatin, potentially affecting immune-related gene expression.
Russian studies claim effects on T-cell subpopulations, including helper and cytotoxic T-cells, though mechanisms are not well characterized.
Proposed to modulate cytokine production including IL-2 and interferons, potentially affecting inflammatory and immune responses.
Note: These pathways are theoretical constructs based on Russian preclinical research. No independent Western validation confirms these mechanisms in humans.
Important Limitations
- 100% of research from Russian institutes (primarily St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication or validation studies
- No controlled human clinical trials demonstrating immune benefits
- Mechanism of action for a simple dipeptide affecting thymus function is not fully characterized
- Pharmacokinetics, bioavailability, and optimal dosing in humans are unknown
- Comparison to established immunomodulators (like Thymosin alpha-1) shows substantial evidence gap
- Translation from animal studies to human immune benefits is completely unconfirmed
Based on preclinical data: Initial interactions with thymic tissue may begin. In vitro studies suggest rapid cellular uptake and chromatin interaction. Any immune parameter changes would not be detectable this early.
PMID:15455093Russian protocols suggest continued treatment during this period. Animal studies show progressive changes in thymic architecture over weeks. Gene expression modifications may develop.
PMID:12360356In aged-mouse studies, extended vilon treatment was associated with lowered biological age, extended lifespan, and reduced spontaneous-tumour incidence in CBA mice. Human response timeline is unknown.
PMID:11140587Long-term effects based on Russian animal studies using cyclical treatment protocols. Optimal human treatment duration and cycling are not established. Sustained immune benefits are unconfirmed.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Thymalin
CompatibleBoth target thymus function - thymalin is a complex thymic extract while Vilon is a simplified synthetic dipeptide. May have overlapping mechanisms in immune modulation.
Thymogen
CompatibleFellow thymic bioregulator peptides from Russian research. Thymogen (EW) and Vilon (KE) represent different dipeptide approaches to thymus support.
Thymosin-Alpha-1
CompatibleBoth target immune function - Ta1 is a 28-amino acid peptide with FDA orphan drug status, while Vilon is a minimal dipeptide approach. Different evidence quality levels.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct targets - Vilon for thymus/immune, epithalon for pineal/longevity. Often used together in Russian protocols.
Selank
CompatibleBoth Russian peptides with immune-related effects - Selank primarily anxiolytic with secondary immune modulation, Vilon specifically targets thymic function.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Vilon
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin · hCAP18 · Human Cationic Antimicrobial Peptide 18 +3
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.